Showing 6461-6470 of 6938 results for "".
- FDA Warns of Adverse Events Associated with Unapproved Use of Expression Injectable as a Dermal Fillerhttps://practicaldermatology.com/news/20140806-fda_warns_of_adverse_events_associated_with_unapproved_use_of_expression_injectable_as_a_dermal_filler/2459150/The FDA reported that it has become aware of adverse events associated with the unapproved use of the Expression product, hyaluronic acid that is packaged in a syringe, as a dermal filler. Events have included swelling, tenderness, firmness, lumps, bu
- National Call-to-Action on Skin Cancer Preventionhttps://practicaldermatology.com/news/20140806-national_call-to-action_on_skin_cancer_prevention/2459152/The American Academy of Dermatology Association (AADA) recently joined with the U.S. Department of Health and Human Services' (HHS) Office of the Surgeon General and Centers for Disease Control and Prevention (CDC) to issue a national call-to-action on skin cancer prevention. T
- Cynosure's PicoSure Laser Cleared by FDA for Acne Scarshttps://practicaldermatology.com/news/20140801-cynosure_announces_picosure_is_fda-cleared_to_treat_acne_scars/2459153/The FDA cleared the PicoSure picosecond laser to treat acne scars. "We are thrilled to announce that PicoSure, the world's most advanced laser technology for tattoo removal and benign pigmented lesions, has now received FDA-clearance to treat acne scar
- FDA Approves of Acticlate Tablets from Aqua Pharmaceuticals, LLChttps://practicaldermatology.com/news/20140728-aqua_pharmaceuticals_llc_announces_fda_approval_of_acticlate_tablets/2459155/The FDA approved Aqua Pharmaceuticals' Acticlate (doxycycline hyclate USP) Tablets, 150 mg and 75 mg, an oral antibiotics for acne. Acticlate is a tetracycline-class antibacterial indicated for the treatment of a number of infections, including adjunctive therapy in severe acne.
- MELA Sciences Reports the Closing of Its Private Placementhttps://practicaldermatology.com/news/20140728-mela_sciences_reports_the_closing_of_its_private_placement/2459156/IRVINGTON, N.Y., July 25, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind(R) system, an optical diagnostic device approved for use in the United States and the European Union to assist dermatologists in melanoma diagnosis, announced today that it has closed i
- TSLMS Presents the 10th Annual SCALE Meetinghttps://practicaldermatology.com/news/20140728-tslms_presents_the_10th_annual_scale_meeting/2459157/The Omni Hotel in Nashville, TN will host the 10th annual SCALE meeting March 6-8, 2015. Sponsored by the Tennessee Society for Laser Medicine & Surgery, the Symposium for Cosmetic Advances and Laser Education is now accepting applications for exhibitors and accepting registrations.
- CSF Unveils New Faculty, Sessions for 2014 Meetinghttps://practicaldermatology.com/news/20140724-csf_unveils_new_faculty_sessions/2459158/Cosmetic Surgery Forum has added new faculty members and educational sessions to its agenda. New to the podium this year will be Joel Cohen, MD, Ellen Marmur, MD, Gerald Goldberg, MD, Michael Greenberg, MD, Sabrina Fabi, MD, and Laurin Council, MD. New sessions include "Polishing Your Neurotoxin Tec
- Innocutis Introduces Cold Sore Dissolvable Tablet to North American Markethttps://practicaldermatology.com/news/20140722-innocutis_introduces_cold_sore_dissolvable_tablet_to_north_american_market/2459160/Innocutis recently introduced Sitavig ®(ACYCLOVIR) 50mg Buccal Tablet to North American markets for the treatment of herpes labialis. Sitavig uses a proprietary delivery technology which consists of a tasteless and odorless tablet that sticks to the gum above the incisor tooth on the side of the lip
- Study: Dermatologists Preferred for Skin Cancer Evaluation and Treatmenthttps://practicaldermatology.com/news/20140722-study_dermatologists_preferred_for_skin_cancer_evaluation_and_treatment/2459161/Dermatologists are overwhelmingly the preferred health care provider for evaluating and treating skin cancer, according to a study published in the June issue of Dermatologic Surgery. In an online survey, respondents were asked their choice for evaluating a worrisome lesion on the face and for remov
- Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of Kerydin in the UShttps://practicaldermatology.com/news/20140721-anacor_pharmaceuticals_and_sandoz_enter_into_an_agreement_for_the_commercialization_of_kerydin_in_the_us/2459163/Anacor Pharmaceuticals, Inc. has entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which Sandoz will distribute and commercialize Anacor's recently approved Kerydin (tavaborole) topical solution, 5% in the US. PharmaDerm, the branded dermatology business of Sandoz